(Q37280244)

19 August 2017

1 reference

title

Tumour vascular disrupting agents: combating treatment resistance (English)

1 reference

19 August 2017

1

G M Tozer

1 reference

19 August 2017

B Vojnovic

5

0 references

author name string

C Kanthou

2

1 reference

19 August 2017

G Lewis

3

1 reference

19 August 2017

V E Prise

4

1 reference

19 August 2017

S A Hill

6

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

British Journal of Radiology

19 August 2017

1 reference

19 August 2017

81 Spec No 1

1 reference

19 August 2017

S12-20

1 reference

Antivascular therapy of cancer: DMXAA.

19 August 2017

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Endothelial-cell proliferation in experimental tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Studies in tissue metabolism: The action of colchicine and B. typhosus extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Vinca alkaloids: anti-vascular effects in a murine tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Combretastatin A4 phosphate: background and current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Tumour targeting by microtubule-depolymerizing vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

The experimental development of bioreductive drugs and their role in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1259%2FBJR%2F36205483

21 January 2018

Identifiers

DOI

10.1259/BJR/36205483

1 reference

19 August 2017

1 reference